Terms: = Colorectal cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR AND Prognosis
11 results:
1. PTPN9 dephosphorylates fgfr2 pY656/657 through interaction with ACAP1 and ameliorates pemigatinib effect in cholangiocarcinoma.
Zhao L; Liu J; Li K; Zhang C; Chen T; Liu Z; Tang Y; Hu X; Shi A; Shu L; Huang S; Lian S; Zhang M; Li H; Sun J; Yu X; Zhang Z; Zhang Z; Xu Y
Hepatology; 2024 Apr; 79(4):798-812. PubMed ID: 37505213
[TBL] [Abstract] [Full Text] [Related]
2. The Emerging Role of Circulating Tumor DNA in Non-colorectal Gastrointestinal cancers.
Lee MS; Kaseb AO; Pant S
Clin Cancer Res; 2023 Sep; 29(17):3267-3274. PubMed ID: 37092904
[TBL] [Abstract] [Full Text] [Related]
3. TNFRSF11B Suppresses Memory CD4+ T Cell Infiltration in the Colon cancer Microenvironment: A Multiomics Integrative Analysis.
Zhang JR; Hou P; Wang XJ; Weng ZQ; Shang-Guan XC; Wang H; You F; Lin BQ; Huang ZY; Chen XQ
Front Immunol; 2021; 12():742358. PubMed ID: 34938284
[TBL] [Abstract] [Full Text] [Related]
4. A comparative study of RTK gene status between primary tumors, lymph-node metastases, and Krukenberg tumors.
Wang B; Tang Q; Xu L; Teng X; Ding W; Ren G; Wang X
Mod Pathol; 2021 Jan; 34(1):42-50. PubMed ID: 32732929
[TBL] [Abstract] [Full Text] [Related]
5. A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases.
Jian M; Ren L; He G; Lin Q; Tang W; Chen Y; Chen J; Liu T; Ji M; Wei Y; Chang W; Xu J
J Transl Med; 2020 Jun; 18(1):234. PubMed ID: 32532289
[TBL] [Abstract] [Full Text] [Related]
6. fgfr2 Promotes Expression of PD-L1 in colorectal cancer via the JAK/STAT3 Signaling Pathway.
Li P; Huang T; Zou Q; Liu D; Wang Y; Tan X; Wei Y; Qiu H
J Immunol; 2019 May; 202(10):3065-3075. PubMed ID: 30979816
[TBL] [Abstract] [Full Text] [Related]
7. Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients.
Gao XH; Yu GY; Hong YG; Lian W; Chouhan H; Xu Y; Liu LJ; Bai CG; Zhang W
Int J Clin Oncol; 2019 Feb; 24(2):141-152. PubMed ID: 30612269
[TBL] [Abstract] [Full Text] [Related]
8. Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
Yoon G; Lee H; Kim JH; Hur K; Seo AN
Tumour Biol; 2016 Aug; 37(8):10209-18. PubMed ID: 26831663
[TBL] [Abstract] [Full Text] [Related]
9. Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy.
Li CF; He HL; Wang JY; Huang HY; Wu TF; Hsing CH; Lee SW; Lee HH; Fang JL; Huang WT; Chen SH
J Clin Pathol; 2014 Dec; 67(12):1056-61. PubMed ID: 25271212
[TBL] [Abstract] [Full Text] [Related]
10. Twist2 is a valuable prognostic biomarker for colorectal cancer.
Yu H; Jin GZ; Liu K; Dong H; Yu H; Duan JC; Li Z; Dong W; Cong WM; Yang JH
World J Gastroenterol; 2013 Apr; 19(15):2404-11. PubMed ID: 23613636
[TBL] [Abstract] [Full Text] [Related]
11. Fibroblast growth factor receptor 2 IIIc as a therapeutic target for colorectal cancer cells.
Matsuda Y; Hagio M; Seya T; Ishiwata T
Mol Cancer Ther; 2012 Sep; 11(9):2010-20. PubMed ID: 22778155
[TBL] [Abstract] [Full Text] [Related]
